Tempus, a leader in AI and precision medicine, has announced the initiation of the GEMINI study in collaboration with AstraZeneca.
The study aims to create a comprehensive multi-omic dataset for patients with Non-small Cell Lung Cancer (NSCLC) to drive future research in precision medicine, diagnostics, and biomarker discovery. Two patient cohorts are being enrolled, one focusing on recently diagnosed Stage IV NSCLC patients receiving checkpoint inhibitor therapy, and the other on early-stage NSCLC patients eligible for surgery.
Tempus will leverage its molecular profiling portfolio and study patients for up to three years to understand tumour biology's impact on disease progression and treatment efficacy. The study will contribute to biomarker discovery, potentially including the use of circulating tumour DNA (ctDNA) testing.
The company will utilise its platform, including intelligent diagnostics, a multimodal data library, and a clinical trial matching program (TIME), to develop a robust multi-omic dataset and ensure broad patient access through its TIME Trial Network.
Click here to read the original news story.